Business
ImmunityBio Presents Favorable Comparative Effectiveness Data in Complete Response Rates of NAI + BCG Versus Nadofaragene and TAR-200 at AUA 2026
ImmunityBio Presents Favorable Comparative Effectiveness Data in Complete Response Rates of NAI + BCG Versus Nadofaragene and TAR-200 at AUA 2026
About this update from Immunitybio, Inc.
[{"type":"text","content":"\nNAI+BCG versus Nadofaragene Results:\n\n\n\nNAI+BCG treated patients were twice as likely to achieve a complete response (CR) at any point of the study versus nadofaragene firadenovec-vncg in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ with or without papillary disease\n\n\n\nMedian duration of CR with NAI+BCG was more than twice that observed with nadofaragene firadenovec-vncg (22.1 versus 9.7 months)\n\n\n\nNAI+BCG reduced cystectomy risk by 60% versus nadofaragene\n\n\n\nNAI+BCG versus TAR-200 Results:\n\n\n\nNAI+BCG demonstrated numerically higher 12-month CR rates and fewer treatment-related adverse events of any grade than TAR-200 (61.7% versus 83.5%)\n\n\n\n CULVER CITY, Calif.--(BUSINESS WIRE)--\nImmunityBio, Inc. (NASDAQ: IBRX), a vertically integrated commercial-stage immunotherapy company, today announced results from two indirect treatment comparison (ITC) analyses presented at the 2026 American Urological Association (AUA) Annual Meeting evaluating nogapendekin alfa inbakicept-pmln (NAI, ANKTIVA®) plus Bacillus Calmette–Guérin (BCG) against two other U.S. Food and Drug Administration (FDA) approved therapies for patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary disease.\n\n\nThe AUA 2026 ITC presentations were:\n\n\n\nPodium presentation - PD25-15 (Edwards et al.): NAI+BCG versus nadofaragene firadenovec-vncg in BCG-unresponsive NMIBC CIS with or without papillary disease\n\n\n\nInteractive poster - IP50-12 (Jayram et al.): NAI+BCG versus TAR-200 in BCG-unresponsive NMIBC CIS with or without papillary disease\n\n\n\nComparative Effectiveness Versus Nadofaragene Firadenovec-vncg\n\n\nIn the absence of head-to-head randomized trials, ImmunityBio conducted a matching-adjusted indirect comparison (MAIC) using individual patient data from QUILT-3.032 (Cohort A, NAI+BCG, n=100) weighted against aggregate data from NCT02773849 (CIS Cohort, nadofaragene firadenovec-vncg, n=103). Baseline matching variables included age (≥65 years), sex, Eastern Cooperative Oncology Group (ECOG) performance status, race, and tumor stage. Effective sample sizes after weighting ranged from 71.7% to 84.2% across endpoints.\n\n\nAfter matching, NAI+BCG demonstrated:\n\n\n\nAnytime CR rate of 69.7% (weighted) versus 53.4% for na...